The purpose of this study is to determine efficacy and safety of repeat administrations of intrathecal injections (into spinal fluid) of NurOwn® (MSC-NTF cells), autologous Mesenchymal Stem Cells [MSC] secreting neurotrophic factors as compared to placebo given three times, each two-months apart.
Contact site for start date.
Please contact ClinicalResearch@sutterhealth.org about this Study.
View study details on ClinicalTrials.gov
Subjects with amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig's disease who are aged 60 years or less, have good breathing (FVC greater than 65%) and who have had weakness for less than 24 months.
June 01, 2018